Suppr超能文献

通过靶向 DCIR 将抗原递呈给人树突状细胞来交叉激活 CD8+ T 细胞。

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

机构信息

Baylor Institute for Immunology Research and Inserm U899, Dallas, TX 75204, USA.

出版信息

Blood. 2010 Sep 9;116(10):1685-97. doi: 10.1182/blood-2010-01-264960. Epub 2010 Jun 7.

Abstract

We evaluated human CD8(+) T-cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. We found the immunoreceptor tyrosine-based inhibitory motif-containing DC immunoreceptor (DCIR) to mediate potent cross-presentation. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8(+) T-cell immunity by all human DC subsets including ex vivo-generated DCs, skin-isolated Langerhans cells, and blood myeloid DCs and plasmacytoid DCs. The delivery of influenza matrix protein (FluMP) through DCIR resulted in expansion of FluMP-specific memory CD8(+) T cells. Enhanced specific CD8(+) T-cell responses were observed when an antigen was delivered to the DCs via DCIR, compared with those induced by a free antigen, or antigen conjugated to a control monoclonal antibody or delivered via DC-SIGN, another lectin receptor. DCIR targeting also induced primary CD8(+) T-cell responses against self (MART-1) and viral (HIV gag) antigens. Addition of Toll-like receptor (TLR) 7/8 agonist enhanced DCIR-mediated cross-presentation as well as cross-priming, particularly when combined with a CD40 signal. TLR7/8 activation was associated with increased expansion of the primed CD8(+) T cells, high production of interferon-γ and tumor necrosis factor-α, and reduced levels of type 2-associated cytokines. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8(+) T-cell immunity.

摘要

我们通过各种凝集素受体评估了针对树突状细胞 (DC) 靶向抗原的人类 CD8(+) T 细胞反应。我们发现含免疫受体酪氨酸抑制基序的 DC 免疫受体 (DCIR) 介导有效的交叉呈递。单次低剂量的抗-DCIR-抗原缀合物暴露即可通过所有人类 DC 亚群启动抗原特异性 CD8(+) T 细胞免疫,包括体外生成的 DC、皮肤分离的朗格汉斯细胞以及血液髓样 DC 和浆细胞样 DC。通过 DCIR 传递流感基质蛋白 (FluMP) 可扩增 FluMP 特异性记忆 CD8(+) T 细胞。与游离抗原或与对照单克隆抗体偶联的抗原或通过另一种凝集素受体 DC-SIGN 传递的抗原相比,当抗原通过 DCIR 传递到 DC 时,观察到增强的特异性 CD8(+) T 细胞反应。DCIR 靶向还诱导针对自身 (MART-1) 和病毒 (HIV gag) 抗原的原发性 CD8(+) T 细胞反应。添加 Toll 样受体 (TLR) 7/8 激动剂增强了 DCIR 介导的交叉呈递和交叉引发,特别是与 CD40 信号结合时。TLR7/8 激活与被激活的 CD8(+) T 细胞的大量扩增、干扰素-γ 和肿瘤坏死因子-α 的高产生以及 2 型相关细胞因子水平的降低有关。因此,通过人 DCIR 受体靶向抗原可激活特定的 CD8(+) T 细胞免疫。

相似文献

7
DCIR interacts with ligands from both endogenous and pathogenic origin.DCIR 与内源性和病原性配体相互作用。
Immunol Lett. 2014 Mar-Apr;158(1-2):33-41. doi: 10.1016/j.imlet.2013.11.007. Epub 2013 Nov 14.

引用本文的文献

6
Cell-targeted vaccines: implications for adaptive immunity.细胞靶向疫苗:对适应性免疫的影响。
Front Immunol. 2023 Aug 16;14:1221008. doi: 10.3389/fimmu.2023.1221008. eCollection 2023.
9
Vaccine adjuvants to engage the cross-presentation pathway.疫苗佐剂以激活交叉呈递途径。
Front Immunol. 2022 Aug 1;13:940047. doi: 10.3389/fimmu.2022.940047. eCollection 2022.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验